LV10042B - The use of certain therapeutically active 4-substituted imidazoles for the manufacture of pharmaceutical preparations to be administered transdermally - Google Patents

The use of certain therapeutically active 4-substituted imidazoles for the manufacture of pharmaceutical preparations to be administered transdermally Download PDF

Info

Publication number
LV10042B
LV10042B LVP-92-19A LV920019A LV10042B LV 10042 B LV10042 B LV 10042B LV 920019 A LV920019 A LV 920019A LV 10042 B LV10042 B LV 10042B
Authority
LV
Latvia
Prior art keywords
drug
transdermal
preparation
formula
compounds
Prior art date
Application number
LVP-92-19A
Other languages
English (en)
Other versions
LV10042A (lv
Inventor
Harry Jalonen
Risto Arvo Sakari Lammintausta
Original Assignee
Orion Yhtym Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Yhtym Oy filed Critical Orion Yhtym Oy
Publication of LV10042A publication Critical patent/LV10042A/lv
Publication of LV10042B publication Critical patent/LV10042B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Claims (6)

  1. LV 10042 DAŽU TERAPEITISKI AKTĪVU 4-AIZVIETOTUIMIDAZOLU PIELIETOŠANA TRANSDERMĀLAS IEDARBĪBAS MEDICĪNISKO PREPARĀTU PAGATAVOŠANAI 5 PATENTA FORMULA 1. Transdermāls preparāts, kas satur terapeitiski aktīvu savienojumu ar formulu 10
    r2 (1) 15
    (2) 20 kur Ri, R2 un R3, kas var būt vienādi vai atšķirīgi, ir H, CH3, C2H5 vai Cl; X ir CH=CHvai (CK^ln, kur n iri līdz 3, vai X ir -C(OR5)H-, kur R5 ir metil- vai etilgrupa; un R4 ir ūdeņradis vai nesazarota alkilgrupa ar 1 līdz 4 oglekļa atomiem. 25
  2. 2. Preparāts, saskaņā ar 1. punktu, kas pagatavots ziedes, emulsijas, gela, losjona, šķīduma vai krēma veidā.
  3. 3. Preparāts, saskaņā ar 1. punktu, kur preparāts ir transdermāla 30 penetrācijas sistēma, kas satur zāļu necaurlaidīgu pamatni un lipīgu slāni, un kur zāles ir disperģētas lipīgajā slānī..
  4. 4. Preparāts, saskaņā ar 1. punktu, kur preparāts ir transdermāla penetrācijas sistēma, kas satur zāļu necaurlaidīgu pamatni, lipīgu slāni un matricu, kurā ir disperģētas zāles. 35 2
  5. 5. Preparāts, saskaņā ar 4. punktu, kur matrica ir izgatavota no polimēra.
  6. 6. Preparāts, saskaņā ar 1. punktu, kur preparāts ir transdermāla penetrācijas sistēma, kas satur zāļu necaurlaidīgu pamatni, lipīgu slāni, zāļu caurlaidīgu membrānu, kas piestiprināta minētās pamatnes vienai pusei, veidojot vismaz vienu zāļu krātuves nodalījumu starp tām, un zāles vai to maisījumu 10 minētajā zāļu krātuvē.
LVP-92-19A 1991-05-31 1992-05-28 The use of certain therapeutically active 4-substituted imidazoles for the manufacture of pharmaceutical preparations to be administered transdermally LV10042B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9111773A GB2256135B (en) 1991-05-31 1991-05-31 Transdermal administration of 4-substituted imidazoles

Publications (2)

Publication Number Publication Date
LV10042A LV10042A (lv) 1994-05-10
LV10042B true LV10042B (en) 1995-02-20

Family

ID=10695905

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-92-19A LV10042B (en) 1991-05-31 1992-05-28 The use of certain therapeutically active 4-substituted imidazoles for the manufacture of pharmaceutical preparations to be administered transdermally

Country Status (18)

Country Link
US (1) US5464628A (lv)
EP (1) EP0586467B1 (lv)
JP (1) JP3269822B2 (lv)
AT (1) ATE199317T1 (lv)
AU (1) AU1780892A (lv)
CA (1) CA2110162C (lv)
DE (1) DE69231709T2 (lv)
DK (1) DK0586467T3 (lv)
EE (1) EE02994B1 (lv)
ES (1) ES2154636T3 (lv)
FI (1) FI935350A0 (lv)
GB (1) GB2256135B (lv)
GR (1) GR3035499T3 (lv)
IE (1) IE66188B1 (lv)
LT (1) LT3005B (lv)
LV (1) LV10042B (lv)
NO (1) NO307365B1 (lv)
WO (1) WO1992021334A1 (lv)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6821196A (en) * 1995-08-14 1997-03-12 Janssen Pharmaceutica N.V. Transdermal administration of vorozole
US5891461A (en) * 1995-09-14 1999-04-06 Cygnus, Inc. Transdermal administration of olanzapine
US5807570A (en) * 1995-09-29 1998-09-15 Cygnus, Inc. Transdermal administration of ropinirole and analogs thereof
GB9614098D0 (en) 1996-07-05 1996-09-04 Orion Yhtymae Oy Transdermal delivery of levosimendan
DE19820151A1 (de) * 1998-05-06 1999-11-11 Hexal Ag Transdermales therapeutisches System zur Anwendung von Candesartan
TW200306783A (en) 2002-04-29 2003-12-01 Fmc Corp Pesticidal heterocycles
FI20041425A0 (fi) * 2004-11-05 2004-11-05 Orion Corp Transmukosaalinen veterinäärinen koostumus
CN101080219B (zh) * 2004-12-15 2010-11-17 帝国制药株式会社 含依托芬那酯的外用贴剂
KR101079914B1 (ko) 2006-01-27 2011-11-04 에프. 호프만-라 로슈 아게 중추신경계 장애를 위한 4-이미다졸 유도체의 용도
DE602007005143D1 (de) * 2006-08-08 2010-04-15 Intervet Int Bv Zusammensetzung für verstärkte antiparasitische wirksamkeit
US7795263B2 (en) * 2008-07-08 2010-09-14 Wildlife Laboratories, Inc. Pharmaceutical combination for and method of anesthetizing and immobilizing non-domesticated mammals
WO2020016827A1 (en) * 2018-07-18 2020-01-23 Clexio Biosciences Ltd. Purified crystalline detomidine hydrochloride monohydrate, anhydrate and free base with low amounts of iso-detomidine and other impurities by recrystallisation in water
CA3137267A1 (en) 2019-05-01 2020-11-05 Clexio Biosciences Ltd. Methods of treating pruritus
CN112220767B (zh) * 2020-09-25 2022-10-25 安徽省公众检验研究院有限公司 一种盐酸阿替美唑缓释片的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU518569B2 (en) * 1979-08-07 1981-10-08 Farmos-Yhtyma Oy 4-benzyl- and 4-benzoyl imidazole derivatives
GB2069481B (en) * 1980-02-13 1983-07-27 Farmos Oy Substituted imidazole derivatives
GB2101114B (en) * 1981-07-10 1985-05-22 Farmos Group Ltd Substituted imidazole derivatives and their preparation and use
GB2167408B (en) 1984-11-23 1988-05-25 Farmos Oy Substituted imidazole derivatives and their preparation and use
US4672344A (en) 1985-04-19 1987-06-09 Siemens Aktiengesellschaft Polarized electromagnetic relay
FI864570A0 (fi) 1986-11-11 1986-11-11 Farmos Oy Terapeutiskt anvaendbar foerening.
US5124157A (en) * 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
FI894911A0 (fi) * 1989-10-17 1989-10-17 Farmos Oy En terapeutiskt vaerdefull foerening.
US5304569A (en) * 1989-11-13 1994-04-19 Orion-Yhtyma Oy Compositions and their use in lowering intraocular pressure

Also Published As

Publication number Publication date
JPH06507618A (ja) 1994-09-01
FI935350A (fi) 1993-11-30
LT3005B (lt) 1994-08-25
IE921938A1 (en) 1992-12-02
EP0586467B1 (en) 2001-02-28
LV10042A (lv) 1994-05-10
DE69231709D1 (de) 2001-04-05
US5464628A (en) 1995-11-07
GR3035499T3 (en) 2001-06-29
GB9111773D0 (en) 1991-07-24
DE69231709T2 (de) 2001-10-04
NO934261L (no) 1993-11-25
ATE199317T1 (de) 2001-03-15
LTIP111A (lt) 1994-03-25
IE66188B1 (en) 1995-12-13
GB2256135B (en) 1995-01-18
FI935350A0 (fi) 1993-11-30
NO934261D0 (no) 1993-11-25
EE02994B1 (et) 1997-06-16
AU1780892A (en) 1993-01-08
WO1992021334A1 (en) 1992-12-10
DK0586467T3 (da) 2001-03-26
JP3269822B2 (ja) 2002-04-02
GB2256135A (en) 1992-12-02
ES2154636T3 (es) 2001-04-16
NO307365B1 (no) 2000-03-27
EP0586467A1 (en) 1994-03-16
CA2110162C (en) 2002-11-12
CA2110162A1 (en) 1992-12-10

Similar Documents

Publication Publication Date Title
CA2110161C (en) Medetomidine preparations for transdermal administration
US4732892A (en) L-α-amino acids as transdermal penetration enhancers
EP0608357B1 (en) Device for administering drug transdermally with a controlled temporal change in skin flux
US5308625A (en) Enhancement of transdermal drug delivery using monoalkyl phosphates and other absorption promoters
US5591767A (en) Liquid reservoir transdermal patch for the administration of ketorolac
EP0676962B9 (en) Enhanced pharmaceutical compositions for skin penetration for piroxicam
EP0586467B1 (en) Pharmaceutical compositions containing 4-substituted imidazoles to be administered transdermally
US4999379A (en) Novel pharmaceutical compositions for topical application with systemic action
IE912108A1 (en) Transdermal administration of buprenorphine
US5358715A (en) Enhancement of transdermal drug delivery using monoalkyl phosphates and other absorption promoters
EP1589973B2 (en) Formulation and methods for the treatment of thrombocythemia
KR100624500B1 (ko) 레리세트론 전달용 경피치료시스템
JP2717859B2 (ja) 経皮吸収製剤
NZ245057A (en) Device for administering drug transdermally comprising a reservoir containing a drug and two solvents with a means for controlling the proportion of each solvent in the reservoir in order to control the drug flux